Laboratory of Neuroimmunology, IRCCS National Neurological Institute C Mondino, University of Pavia, Italy.
J Neuroimmunol. 2011 Jan;230(1-2):160-3. doi: 10.1016/j.jneuroim.2010.10.027. Epub 2010 Nov 24.
We measured circulating serum and cerebrospinal fluid (CSF) concentrations of B lymphocyte activating factor of the tumour necrosis factor superfamily (BAFF), and determined total and Epstein-Barr virus (EBV)-specific oligoclonal IgG bands (OCBs) in 43 patients with multiple sclerosis (MS), 23 patients with other inflammatory demyelinating neurological diseases, and 20 patients with non-inflammatory neurological diseases. Serum and CSF BAFF concentrations did not differ in the three studied groups. In MS, the highest BAFF concentrations were found in the CSF samples with more than 6 OCBs (233.1 ± 129.5 vs 79.2 ± 51.6 pg/mL in the samples with less than 7 OCBs, p<0.0001). Irrespectively from BAFF levels, EBV-specific OCBs were detected in MS and in the other non-inflammatory and inflammatory demyelinating neurological diseases, with a similar frequency, and as a 'mirror pattern' in 30 of 33 EBV-specific OCB-positive cases (p<0.0001). These results indicate that circulating CSF BAFF concentrations cannot help differentiate MS from other inflammatory demyelinating neurological diseases, but positively associates with the qualitative expression of elevated intrathecal IgG production in MS, and that the oligoclonal EBV-specific antibody response, when present, is mostly systemic in all the studied neurological patients, and not preferentially restricted to MS.
我们测量了 43 例多发性硬化症(MS)患者、23 例其他炎症性脱髓鞘性神经疾病患者和 20 例非炎症性神经疾病患者的循环血清和脑脊髓液(CSF)中肿瘤坏死因子超家族 B 淋巴细胞激活因子(BAFF)浓度,并确定了总和 Epstein-Barr 病毒(EBV)特异性寡克隆 IgG 带(OCB)。在这三组研究对象中,血清和 CSF BAFF 浓度没有差异。在 MS 中,CSF 样本中 BAFF 浓度最高的是 OCB 超过 6 个的样本(233.1±129.5 pg/mL 比 OCB 少于 7 个的样本,p<0.0001)。无论 BAFF 水平如何,MS 以及其他非炎症性和炎症性脱髓鞘性神经疾病中都检测到了 EBV 特异性 OCB,其频率相似,并且在 33 例 EBV 特异性 OCB 阳性病例中有 30 例呈“镜像模式”(p<0.0001)。这些结果表明,循环 CSF BAFF 浓度不能帮助区分 MS 与其他炎症性脱髓鞘性神经疾病,但与 MS 中鞘内 IgG 产生的定性表达呈正相关,而当存在时,寡克隆 EBV 特异性抗体反应在所有研究的神经疾病患者中大多是全身性的,而不是优先局限于 MS。